Skip to main content
OpenTrials
Completed

NCT Number: NCT04514198

Postoperative Pancreatitis and Its Correlation With Clinically Relevant Pancreatic Fistula in Pancreaticoduodenectomy

AIM

To determine association between postoperative pancreatitis and pancreatic fistula

OBJECTIVES

1. To determine incidence of Clinically relevant pancreatic fistula (grade B/C) after pancreaticoduodenectomy 2. To determine role of serum amylase levels on day 1 to predict clinically relevant pancreatic fistula 3. To determine risk factors for postoperative pancreatitis and postoperative pancreatic fistula

Primaryendpoint:

Incidence of post operative pancreatitis and post operative pancreatic fistula.

Secondaryendpoints:

1. to identify the possible predictors of post operative pancreatitis. 2. to investigate the association between post operative pancreatitis and post operative pancreatic fistula.

MATERIAL AND METHODS

Study centre:

Inpatient admissions in Department of gastroenterology, Asian institute of gastroenterology, Hyderabad

Study population:

Patients who are supposed to undergo pancreaticoduodenectomy Study design: Prospective observational study

Study period:

Study will be conducted till desired sample size achieved or March 2020 to march 2022

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Asian Institute of Gastroenterology/AIG Hospitals

Hyderabad, Telangana, 500082, India

About this study

STUDY PROCEDURE:

Demographic, pathological and intraoperative data will be recorded in a prospectively maintained database populated from a combination of electronic patient records, preoperative imaging and anaesthetic charts. Preoperative clinical data included age, gender, body mass index (BMI), and the results of serum biochemical investigations including serum bilirubin, urea and amylase. The serum amylase measured throughout the study period is total amylase. Preoperative computed tomography images will beanalyzed to calculate pancreatic duct diameter at the line of transection of the pancreas anterior to the portal vein. Intraoperative data included reconstruction technique, texture of the pancreatic remnant and estimated blood loss. Blood loss data will be compiled from a combination of anaesthetic charts and perioperative blood transfusion data. Specimens will be dichotomized according to whether their pathology was associated with hard pancreatic parenchyma [pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis] or with soft or normal pancreatic parenchyma (ampullary carcinoma, duodenal carcinoma, cholangiocarcinoma, neuroendocrine tumours and other lesions). Outcome data included length of stay in a critical care environment [defined as either an intensive care unit (ICU) or a surgical high-dependency unit (SHDU)] and length of postoperative hospital stay. All postoperative complications will be prospectively recorded and graded according to the International Study Group on Pancreatic Fistula (ISGPF) and International Study Group of Pancreatic Surgery (ISGPS) classifications and the Clavien-Dindo classification. Complications of ISGPS Grades B and C and Clavien-Dindo Grades III-V are considered clinically significant. Mortality will be recorded at 30-day and 90-day time-points.

Serum amylase will be systematically measured on POD1 and POD3 according to our institutional policy. No additional radiological or laboratory studies are required for the diagnosis of postoperative pancreatitis. No specific protocols for the treatment of POP will be followed during the study period because none are available. Due to the absence of a widely accepted definition, POP is defined according to Connor's definition1 as an elevation in serum pancreatic amylase above the upper limit of normal on postoperative day (POD) 0 or 1. At our institution, the upper limit of normal for serum pancreatic amylase is 100 U/L.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients (>18 yrs) undergoing elective Whipple's PD in Asian institute of gastroenterology, Hyderabad, Telangana.

Exclusion criteria

  • On table inoperable patients
  • Patients in cholangitis or bilirubin > 15 mg/dl
  • Patients not giving consent for participation
  • Patients with acute inflammatory states (cholangitis, sepsis, trauma, acute on chronic pancreatitis)

Treatment and study plan

Primary outcomes

  1. To estimate incidence of Post operative Pancreatitis and post operative pancreatic fistula among patients undergoing pancreaticoduodenectomies.

    Time frame: 10 days

    After pancreaticoduodenectomy surgery, pancreatitis occurs it is a local inflammatory process occurring in the area of the pancreatic anastomosis after pancreas resection could induce increased systemic amylase concentration, Amylase normal range is 28--100, if it exceeds the upper normal limits it leads to post operative pancreatitis, pancreatic fistula is defined as persistent drainage of amylase rich fluid (3x > than upper limit of normal serum amylase) for greater than 3 days.

Sponsors and collaborators

Lead sponsor

Asian Institute of Gastroenterology, India

Other

Registry information

Official study title

Postoperative Pancreatitis and Its Correlation With Clinically Relevant Pancreatic Fistula in Pancreaticoduodenectomy- A Prospective Observational Study

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Aug 14, 2020
Registry last updated
Jan 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.